Supernus Pharmaceuticals
SUPN
244 hedge funds and large institutions have $1.86B invested in Supernus Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 91 increasing their positions, 76 reducing their positions, and 19 closing their positions.
105% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 19
30% more capital invested
Capital invested by funds: $1.42B → $1.86B (+$433M)
20% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 76
8% more funds holding
Funds holding: 225 → 244 (+19)
1.55% more ownership
Funds ownership: 102.49% → 104.05% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
23% less call options, than puts
Call options by funds: $2.16M | Put options by funds: $2.79M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.7M |
| 2 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$9.4M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$7.93M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$7.33M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Chicago,
Illinois
|
-$11.5M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$7.46M |
| 3 |
Millennium Management
New York
|
-$7.06M |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$5.03M |
| 5 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
-$4.63M |
SUPN Hedge Fund Activity: Q3 2022 in Review
244 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2022, worth a combined $1.86B — up 30% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new SUPN positions and 19 closed out — a net gain of 20 holders — while 91 added to existing stakes and 76 trimmed.
The largest buyer was BlackRock, adding an estimated $13.7M. The largest seller was Mesirow Financial Investment Management - Fixed Income, exiting entirely with an estimated $11.5M sold.
- 244 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2022, up from 225 in Q2 2022.
- Funds reported $1.86B of Supernus Pharmaceuticals stock for Q3 2022, up 30% quarter-over-quarter.
- 39 funds opened new Supernus Pharmaceuticals positions in Q3 2022 and 19 closed out, a net change of +20 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2022 was BlackRock, an estimated $13.7M added.
- The largest Supernus Pharmaceuticals seller in Q3 2022 was Mesirow Financial Investment Management - Fixed Income, an estimated $11.5M sold.
Based on aggregated 13F filings for Q3 2022.